2019
DOI: 10.1111/imj.14269
|View full text |Cite
|
Sign up to set email alerts
|

Characteristics, risk factors and management of venous thromboembolism in immune thrombocytopenia: a retrospective multicentre study

Abstract: Background: An increased risk of thrombosis has been reported in immune thrombocytopenic purpura (ITP), but the characteristics, risk factors of occurrence, recurrence and management of venous thromboembolic events (VTE) have been poorly investigated.Aims: To describe VTE and ITP characteristics, distribution of VTE risk factors and their impact on VTE features and recurrence.Methods: A retrospective study of patients with ITP and VTE registered in databases of three reference French centres of ITP.Results: Am… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

3
16
0

Year Published

2019
2019
2024
2024

Publication Types

Select...
7

Relationship

0
7

Authors

Journals

citations
Cited by 18 publications
(20 citation statements)
references
References 30 publications
3
16
0
Order By: Relevance
“…18 While classical (e.g., advanced age, obesity, hormonal contraceptives, pregnancy/puerperium, cancer, recent surgery, history of VTE) and treatment-related risk factors (e.g., corticosteroids, high-dose intravenous immunoglobulins [IVIGs], splenectomy) contribute to the etiopathogenesis of VTE in ITP, thrombocytopenia does not protect against thrombosis. 19 Likewise, anticoagulation seems to be feasible in most patients with ITP and VTE despite persistently low platelet counts, which is consistent with a bleeding protective effect of increased IPFs. 19 Expert guidance on how to approach ITP patients with VTE or arterial thrombosis has recently been published.…”
Section: Specific Hematological Disorders Immune Thrombocytopeniasupporting
confidence: 53%
“…18 While classical (e.g., advanced age, obesity, hormonal contraceptives, pregnancy/puerperium, cancer, recent surgery, history of VTE) and treatment-related risk factors (e.g., corticosteroids, high-dose intravenous immunoglobulins [IVIGs], splenectomy) contribute to the etiopathogenesis of VTE in ITP, thrombocytopenia does not protect against thrombosis. 19 Likewise, anticoagulation seems to be feasible in most patients with ITP and VTE despite persistently low platelet counts, which is consistent with a bleeding protective effect of increased IPFs. 19 Expert guidance on how to approach ITP patients with VTE or arterial thrombosis has recently been published.…”
Section: Specific Hematological Disorders Immune Thrombocytopeniasupporting
confidence: 53%
“…A retrospective analysis of 49 patients with ITP and VTE managed across three French ITP centres identified APL antibodies in 40% of the cohort, which was not in excess of that expected in ITP patients in general. 17 Altogether, 165 patients with ITP were monitored for the development of thrombotic events over a mean period of approximately five years. Of these, 42% had detectable APL antibodies (anti-cardiolipin or anti-b 2 glycoprotein) or were positive for a lupus anticoagulant according to the diluted Russell viper venom time (DRVVT).…”
Section: Thrombosis With Untreated Itpmentioning
confidence: 99%
“…Whether the presence of APL antibodies in ITP contributes to thrombogenesis has been questioned by several groups. A retrospective analysis of 49 patients with ITP and VTE managed across three French ITP centres identified APL antibodies in 40% of the cohort, which was not in excess of that expected in ITP patients in general 17 . Altogether, 165 patients with ITP were monitored for the development of thrombotic events over a mean period of approximately five years.…”
Section: Thrombosis With Untreated Itpmentioning
confidence: 99%
See 1 more Smart Citation
“…This has been addressed in a recent follow-up study of 49 ITP cases. Twenty seven percent patients with VTE and ITP had a recurrent VTE after a median delay of 110 months (range, 8-401 months), and median thrombosis-free survival was 8.8 months [10]. This study, and index case suggests that long-term (or indefinite) anti-coagulation is reasonable in ITP patients, especially those who have an unprovoked VTE, or recurrent VTE.…”
mentioning
confidence: 67%